<DOC>
	<DOC>NCT01072435</DOC>
	<brief_summary>Propofol is a drug of choice for deep sedation in endoscopy. Propofol can be administered in many ways: by infusion or intravenous boluses and with self-administration device (patient-controlled sedation; PCS). It is not clear which method of propofol administration would be preferable. The main objective of the trial is to compare 2 different methods of propofol administration during ERCP: patient-controlled administration(PCS) and target-controlled infusion (TCI).</brief_summary>
	<brief_title>Target-controlled Infusion Versus Patient-controlled Sedation With Propofol in Endoscopic Retrograde Cholangiopancreatography (ERCP)</brief_title>
	<detailed_description>80 patients of age 18-75 undergoing elective ERCP will be included to the randomized non-commercial clinical trial. Exclusion criteria are: allergy to the opioids or propofol, dementia, mental retardation, severe liver or kidney insufficiency, significant heart failure or lung disease, drug addiction. The endpoints are: ease of procedures performance, complications, degree of sedation, recovery time, propofol and opioid consumption. During the procedure patients observed and treated by the anaesthesiologist and anaesthesia nurse .</detailed_description>
	<mesh_term>Propofol</mesh_term>
	<criteria>elective ERCP patients allergy to propofol or opioid; inability to cooperate; ASA(American Society of Anaesthesiology)class greater than 3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>ERCP</keyword>
	<keyword>patient-controlled sedation</keyword>
	<keyword>target-controlled infusion</keyword>
	<keyword>propofol</keyword>
	<keyword>Sedation with propofol for ERCP</keyword>
	<keyword>Endoscopic Retrograde Cholangiopancreatography</keyword>
</DOC>